Achieving Benchmarks for National Quality Indicators Reduces Recurrence and Progression in Non–muscle-invasive Bladder Cancer Article Swipe
Related Concepts
Medicine
Bladder cancer
Cancer
Oncology
Internal medicine
Paramananthan Mariappan
,
Allan Johnston
,
Matthew Trail
,
Sami Hamid
,
Graham Hollins
,
B. Dreyer
,
Sara Ramsey
,
Luisa Padovani
,
Roberta Garau
,
Julia Guerrero Enriquez
,
A. Boden
,
Gianluca Maresca
,
Helen Simpson
,
Rami Hasan
,
Claire C. Sharpe
,
Benjamin G. Thomas
,
Chaudhry Altaf
,
Rehan Khan
,
Jaimin R. Bhatt
,
Imran Ahmad
,
G.M. Nandwani
,
Konstantinos Dimitropoulos
,
Lydia Makaroff
,
Johnstone Shaw
,
Catriona Graham
,
David Hendry
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.euo.2024.01.012
· OA: W4391339416
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.euo.2024.01.012
· OA: W4391339416
Following the first 3 yr of implementing a novel quality performance indicator programme in Scotland, we evaluated compliance and outcomes in non-muscle-invasive bladder cancer. In 2688 patients followed up for 5 yr, we found that achieving targets for sampling detrusor muscle and the single instillation of mitomycin C during and after transurethral resection of bladder tumour, respectively, were associated with delays in cancer recurrence and progression.
Related Topics
Finding more related topics…